The ICH S9 Guideline Q&A document – published in June 2018 – is designed to clarify some of the most common challenges experienced across the industry when implementing ICH S9. Here, Robert Turcan at Envigo highlights a few key areas selected based on the advice sought by their customers during the development of their anti-cancer pharmaceuticals. He concludes with a consideration of the outlook for oncology programmes, as well as recent FDA approvals.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/04/Non-clinical-evaluations-for-anti-cancer.pdf” width=”100%” height=”900px” style=”border:0;”]